The research, conducted entirely in silico using advanced quantum chemical methods, modeled the behavior of Mg(II), Fe(II), Fe(III), Co(II), Co(III) and Cu(II) porphyrines under static magnetic fields ranging from 0.1 to 100 Arbitrary Magnetic Field Units, where one AMFU exceeds 1000 Tesla. The team used density functional theory with the B3LYP functional and a 6-31G** basis set, drawing initial structures in Fujitsu Scigress 2.0, optimizing them in Gaussian 0.9, and then applying the Amsterdam Modelling Suite with a non-relativistic orbital momentum L-dot-B method to simulate the field’s influence before recalculating structural and electronic properties.

The results reveal a consistent pattern: static magnetic fields decreased the stability of every metalloporphyrine examined. The researchers measured this through heat of formation, where less negative values indicate reduced stability. Across all six metal centers, the heat of formation became progressively less negative as flux density increased. For Mg(II) porphyrine, considered a simplified model of chlorophyll, the value shifted from -803 kJ·mol⁻¹ at zero field to -698 kJ·mol⁻¹ at 100 AMFU when the molecule was oriented along the X-axis. The effect depended strongly on how the molecule sat within the Cartesian coordinate system, with X-axis orientation generally producing the strongest destabilization, followed by Y- and Z-axes.

Alongside the loss of stability came a rise in dipole moment, signaling growing molecular asymmetry. The macrocyclic ring, normally flat with D4h symmetry, lost its planarity under the field’s influence. The deformed skeletons adopted one of four characteristic conformations: saddle, ruffle, dome or wave. In Mg(II) porphyrine specifically, the central magnesium atom was ejected from the molecular center as Mg-N bond lengths increased, stretching from roughly 1.9 Å at zero field to over 2.4 Å at the highest flux density along the X-axis.

The electronic consequences were equally significant. Charge density at the ring nitrogen atoms changed irregularly with increasing field strength, and the Mg-N bonds, described as intermediate between ionic and atomic in character, weakened as the external magnetic field reduced the durability of the binding electron pair. The positive charge on the central magnesium atom rose with flux density, which the authors note should enhance its ability to bind Lewis bases and potentially promote photosynthesis, provided the reaction site is not obscured by steric hindrance from the deformed ring.

Iron porphyrines, representing heme and hemin, showed their own distinct responses. The Fe(II) molecule was already non-planar before any field was applied, and the static magnetic field deepened its deformation. Remarkable elongation of some C-H bonds occurred at 10 and 100 AMFU when the molecule sat in the X-Y plane. The positive charge density at the iron atom generally decreased with increasing flux density along the X-axis but increased along the Z and Y axes, a pattern the authors describe as beneficial for accepting Lewis bases such as carbon monoxide. Fe(III) porphyrine, by contrast, resisted deformation more effectively along the X and Z axes, though its iron atom also showed irregular charge shifts and its N-Fe bonds generally lengthened with rising field strength.

Cobalt porphyrines, the structural basis of vitamin B12, behaved differently again. The Co(II) atom, being bidentate, largely inhibited the bending deformation seen in other metalloporphyrines, instead producing local distortion within the macrocycle. When the field acted along the Z-axis, the molecule flattened, cycling through dome-flat-flat-dome conformations as flux density increased. Along the X or Y axis, a wave-mode deformation emerged. Notably, the positive charge density at the Co(II) atom always increased relative to the field-free state, enhancing its capacity to bind Lewis bases, with Y-axis orientation producing the most reactive configuration. The Co(III) cation, however, moved in the opposite direction: field exposure decreased its ability to coordinate Lewis bases, and its presence favored elongation of C-H bonds to a degree suggesting possible dissociation.

Cu(II) porphyrine, the model for hemocyanin in blue-blooded invertebrates, presented perhaps the most unusual behavior. Even without any applied field, both nitrogen atoms bound to copper carried positive charge density, a rarity among the molecules studied. A field of just 0.1 AMFU flipped the charge at N1 to negative when the molecule was oriented along the X or Z axis, while the Y-axis orientation required the full 100 AMFU to achieve the same conversion. The positive charge on the copper atom itself invariably increased with field strength, which should facilitate coordination of Lewis bases, though the N-Cu bond lengths varied irregularly and were least sensitive to elongation along the Z-axis.

Ranking the six metalloporphyrines by stability loss under the field, the order from most to least affected was Fe(III)⁺, Co(III)⁺, Fe(II), Co(II), Cu(II) and Mg(II). The authors conclude that static magnetic fields, even at the lowest simulated flux density of 0.1 AMFU, influence the biological role of metalloporphyrines through changes in electron density at the central metal atoms, steric hindering of the deformed ring, and polarization of bonds from pure valence character toward ionic character. Regardless of orientation along the X, Y or Z axes, the field always destabilized the molecules, and the resulting deformation facilitated additional ligation of the central metal atom, an effect the researchers suggest could potentially be harnessed in synthetic modifications of metalloporphyrines.

The findings carry a speculative connection to astrophysics. The authors note the recent discovery of the highest-energy cyclotron resonance scattering feature from the galactic ultraluminous X-ray pulsar Swift J0243.6+6124, where magnetic fields exceed 1.6 billion Tesla near the surface of the neutron star. Such extreme fields, they argue, reinforce the plausibility that high-density static magnetic fields genuinely deteriorate metalloporphyrine integrity, lending cosmic-scale weight to the computational predictions. While the simulations remain theoretical and the Arbitrary Magnetic Field Unit vastly exceeds typical terrestrial exposures, the work opens a provocative question about whether the magnetic environments surrounding living systems, from MRI scanners to planetary fields, might subtly reshape the chemistry of life’s most essential metal complexes.

Subject of Research: Numerical simulation of static magnetic field effects on biologically essential metalloporphyrines

Article Title: Potential risk resulting from the influence of static magnetic field upon living organisms. Numerically simulated effects of the static magnetic field upon metalloporphyrines

Article References: Ciesielski, W., Girek, T., Oszczęda, Z., Soroka, J. A., & Tomasik, P. (2022). Potential risk resulting from the influence of static magnetic field upon living organisms. Numerically simulated effects of the static magnetic field upon metalloporphyrines. BioRisk, 18, 115-132. https://doi.org/10.3897/biorisk.18.86616

Image Credits: AI Generated

DOI: 10.3897/biorisk.18.86616

Keywords: static magnetic field, metalloporphyrines, porphine, chlorophyll, heme, vitamin B12, hemocyanin, density functional theory, molecular deformation, charge density, BioRisk, computational chemistry

TH17 cells are an IL-17A-secreting subset of CD4+ T effector cells that defend against invading extracellular pathogens, maintaining immunity at skin and mucosal barriers under homeostatic conditions. In addition to IL-17A, they produce IL-17F, IL-21, and IL-22, recruiting other pro-inflammatory mediators to promote pathogen clearance. But when their activation goes awry, TH17 cells become key drivers of several autoimmune and chronic inflammatory diseases, including multiple sclerosis, psoriasis, and inflammatory bowel disease. While IL-17A/IL-17R neutralizing antibodies have found success in treating psoriasis, they have had limited success in inflammatory bowel disease, suggesting that targeting factors that broadly regulate TH17 cell function may be more effective. The lineage-defining transcription factor RORγt drives TH17 development, but a complex network of additional transcription factors works in concert to promote or inhibit TH17-mediated inflammation. The Solt laboratory previously identified that REV-ERBα acts as a negative regulator of the TH17 program in vitro and in vivo, and that REV-ERB-selective synthetic ligands mediated protection against TH17-driven diseases in mouse models of multiple sclerosis and ulcerative colitis. However, those ligands targeted both REV-ERBs or REV-ERBα alone, leaving the physiological function of REV-ERBβ in T cell effector responses largely unexplored.

To establish whether REV-ERBβ is required to limit TH17-mediated pro-inflammatory responses in vivo, the team used REV-ERBβ-deficient mice in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Immune phenotyping revealed no overt differences in thymocyte or T cell composition between wild-type and knockout animals under steady-state conditions. But when the researchers immunized both groups with myelin oligodendrocyte glycoprotein peptide (MOG35-55) and monitored disease daily, the knockout mice fared dramatically worse. Mean maximum disease score reached 3.57 in REV-ERBβ-deficient mice relative to 2.05 in wild-type littermates—a statistically significant difference—and the mean day of disease onset was also earlier, at 10.43 versus 11.62 days. Flow cytometric analysis of the central nervous system at the peak of disease revealed an increased frequency and number of CD4+ T cells infiltrating the CNS of knockout animals. The disease phenotype was not attributable to increased frequencies of CD4+CCR6+ cells or decreased frequencies of anti-inflammatory Foxp3+ T regulatory cells, as no differences were observed between genotypes. However, the frequency and number of CD4+RORγt+ cells were elevated in the knockout CNS, and while no statistically significant increase in IL-17A+ T cells was detected, there was a significant increase in the frequency and number of the IL-17A+IFNγ+ population—a double-positive subset whose acquisition of IFNγ has been linked to pathogenicity in several models of chronic disease, including EAE and multiple sclerosis.

Because the EAE model involved global deletion of REV-ERBβ, the excessive neuroinflammation could theoretically have stemmed from direct effects on microglia or other immune cell types rather than T cells themselves. To specifically assess T-cell-mediated effects, the researchers sorted naive CD4+ T cells from wild-type and REV-ERBβ-deficient mice and adoptively transferred them into Rag1-deficient recipients to track the development of colitis, another TH17-driven inflammatory disorder. Over a 12-week experiment, transfer of REV-ERBβ-deficient cells resulted in more severe weight loss and increased colon weight, a function of increased immune cell infiltration leading to exacerbated intestinal inflammation. Colon weight/length ratios—a measure that controls for measurement bias and reflects inflammation and edema—were also higher in mice receiving knockout cells, indicative of more intestinal inflammation. Quantitative real-time PCR of proximal colon tissue revealed significantly increased expression of the pro-inflammatory cytokine genes Il17a, Il17f, Il6, Tnf, and Ifng in mice receiving REV-ERBβ-deficient T cells compared to wild-type recipients. Expression of Il22 was also elevated but did not reach statistical significance, and Cxcl10—a gene activated downstream of IL-17 and IL-22 signaling—was increased, consistent with an overall heightened TH17 pro-inflammatory profile in vivo.

In a shorter-term experiment sacrificed at five to six weeks post-transfer, when T cells are just beginning to enter the colon, mice receiving REV-ERBβ-deficient T cells again showed increased colon weight and higher colon weight/length ratios. Flow cytometry revealed increased infiltration of total immune cells and increased frequency and number of CD3+CD4+ T cells in the mesenteric lymph nodes and colons of knockout-cell recipients, with no differences observed in the spleen. While mice receiving knockout cells did not show increased frequencies of CD4+RORγt+ or RORγt+IL-17A+ TH17 cells, there were increased absolute numbers of both populations in the colons. NanoString experiments on FACS-sorted T cells isolated from the colons confirmed increased expression of pro-inflammatory cytokines and chemokines, including Cxcl10, Ccr9, and Il22. Intriguingly, genes involved in oxidative stress and apoptosis—including Sod1, Bcl2, Casp3, Casp8, and Xiap—were decreased in REV-ERBβ-deficient T cells, suggesting the receptor may regulate apoptosis and cell survival in T cells within the colon. Expression of Il18rap was also downregulated; this receptor acts as a negative regulator of TH17 cell differentiation in the intestine, and its dysfunction is linked to intestinal diseases like Crohn’s disease, inflammatory bowel disease, and celiac disease.

To model REV-ERBβ-dependent T cell functions in vitro, the team tested the requirement for the receptor to limit pro-inflammatory cytokine expression in CD4+ T helper cells using congenic co-cultures. Naive CD4+ T cells from congenic CD45.1 wild-type and CD45.2 REV-ERBβ-deficient mice were differentiated under three different TH17 polarizing conditions: non-pathogenic (TGFβ plus IL-6), pathogenic 1 (TGFβ, IL-6, and IL-23), and pathogenic 2 (IL-6, IL-1β, and IL-23). Loss of REV-ERBβ decreased the ratio of knockout to wild-type cells in all three cultures, suggesting a cell-extrinsic effect on proliferation or survival. Despite the decreased frequency of knockout cells in culture, REV-ERBβ deficiency led to increased IL-17A production under non-pathogenic and pathogenic 1 conditions but not pathogenic 2 conditions, hinting at a potential requirement for TGFβ in the receptor’s regulatory effects. Carboxyfluorescein succinimidyl ester (CFSE) staining revealed no overt defects in proliferation, but a viability dye showed increased non-viable cells in knockout cultures, consistent with the decreased expression of Sod1, Bcl2, and Xiap seen in the NanoString data. These effects appear specific to TH17 cells, as loss of REV-ERBβ did not affect TH1 or inducible T regulatory cell differentiation.

To address whether REV-ERBβ affects TH17 cell function through cell-intrinsic or cell-extrinsic mechanisms in vivo, the researchers performed co-transfer experiments using the T cell transfer model of colitis, mixing equal numbers of congenic CD45.1+ wild-type and CD45.2+ REV-ERBβ-deficient naive CD4+ T cells before injection into Rag1-deficient recipients. After six weeks of expansion, there were decreased REV-ERBβ-deficient cells in the mesenteric lymph nodes and colon lamina propria, corroborating the in vitro data. Upregulation of the chemokine receptor CCR9 and the integrin α4β7 in mesenteric lymph nodes mediates lymphocyte homing to the intestinal lamina propria. While CCR9 expression was increased in REV-ERBβ-deficient T cells in the lymph nodes and colon, the knockout cells did not have an advantage homing to these sites. Despite this, REV-ERBβ-deficient T cells exhibited increased frequency of RORγt+ cells and RORγt+IL-22+ cells in the colons, along with increased frequency of IL-17A+IFNγ+ cells. These results demonstrate that REV-ERBβ is required to control T cell accumulation at inflammatory sites as well as temper downstream TH17 pro-inflammatory responses in a cell-intrinsic manner.

To gain a better understanding of the transcriptional programs controlled by each receptor, the team performed RNA-sequencing on TH17 cells collected at peak mRNA expression of each REV-ERB: time zero (naive) for REV-ERBβ and 24 hours post-activation for REV-ERBα. The results were striking. At both time points, there was very little overlap in transcriptional signatures between REV-ERBβ-deficient and REV-ERBα-deficient T cells. The genes that did overlap fell under metabolic pathways via KEGG analysis. At time zero, REV-ERBβ regulated a large number of pathways relative to REV-ERBα, including genes involved in the cell cycle (Ccnd2, Ccnd3, Ccnb1), whereas REV-ERBα regulated genes involved in circadian rhythm, consistent with its role as a core member of the circadian clock. REV-ERBβ also appeared to regulate genes involved in FoxO, JAK-STAT, and PI3K-Akt signaling pathways at time zero. In TH17 cells at 24 hours, REV-ERBβ regulated genes involved in Polycomb repressive complexes, Notch signaling, regulation of the actin cytoskeleton, and cellular senescence, whereas REV-ERBα regulated genes involved in CD4+ T cell differentiation, including TH1, TH2, and TH17 lineages. RT-qPCR further confirmed that post-activation, REV-ERBα was upregulated similar to RORγt, while REV-ERBβ was downregulated upon TH17 cell differentiation—a divergent expression pattern in contrast to what is observed in other tissues.

Because REV-ERBα’s repressive function is largely instilled by the co-repressor NCoR1, and homology led many to assume REV-ERBβ works similarly, the researchers probed whether this holds true. Mammalian two-hybrid assays in HEK293 cells demonstrated that the REV-ERBβ ligand binding domain can interact with NCoR1 in a dose-dependent manner. However, overlay of publicly available NCoR1 ChIP-seq peaks with differentially expressed genes from naive REV-ERBβ-deficient T cells revealed very little overlap—only 34 shared target genes. The overlapping genes were related more toward overall T cell activation and proliferation (Cd69, Ctse, Ccnd2, Ccnd3, Icos, Il7r, Ptpn22) than TH17 lineage specification. To determine whether REV-ERBβ represses transcription passively by displacing RORs from shared DNA binding sites or actively by recruiting co-repressor proteins, the team generated retroviral constructs encompassing the DNA binding domain alone (βDBD) or all but the DNA binding domain (βΔDBD), along with a heme binding mutation (βHBM, H565F) that reduces heme binding affinity more than 10,000-fold. When overexpressed in TH17 cells, the truncation and deletion constructs were unable to repress Il17a relative to wild-type REV-ERBβ, indicating that active repression requires both DNA binding and cofactor recruitment via the ligand binding domain. Remarkably, the heme binding mutation did not relieve repression at IL-17A, and RNA-sequencing showed it had little effect on transcription, relieving repression of only about 10–15% of wild-type target genes. These data suggest REV-ERBβ functions in a largely heme-independent manner in TH17 cells—a non-canonical signaling mechanism that contrasts sharply with REV-ERBα, whose heme-dependent NCoR1 interaction recruits the histone deacetylase HDAC3 to repress transcription at Il17a.

The findings carry significant therapeutic implications. Several small molecules targeting both REV-ERBα and REV-ERBβ have been developed as alternatives to RORγt modulators, and the Solt laboratory recently developed a ligand selective for REV-ERBα over REV-ERBβ. But the current data suggest that targeting both factors would be ideal to better encompass inhibition of the TH17 program in vivo—both during the initial development of TH17 cells, when REV-ERBβ is more highly expressed, and later post-activation, when REV-ERBα dominates. By this logic, ligands that target both REV-ERBs would have a greater repressive effect than a ligand targeting only a single receptor subtype. The work also raises a compelling paradox: in vivo, REV-ERBβ-deficient TH17 cells accumulate at lesion sites, yet in vitro they exhibit increased cell death. The researchers suggest that in vivo, these cells may reside in a supportive ecosystem, interacting with stromal cells and antigen-presenting cells that provide survival signals absent in culture. Future experiments testing competition, cell death versus proliferation, and accumulation under both conditions would tease out this contradiction. The team acknowledges limitations, including the use of retroviral overexpression rather than endogenous gene editing, the lack of ChIP-grade REV-ERBβ antibodies to map binding sites, and the inability to completely rule out REV-ERBβ’s independence from REV-ERBα using single knockout systems. Nevertheless, the study establishes for the first time that individuality exists between the two REV-ERB receptors in TH17 cells, suggesting they complement each other in a spatiotemporal network rather than overlapping patterns—a discovery that reshapes how scientists think about circadian nuclear receptors in immunity and opens new avenues for treating TH17-driven autoimmune disease.

Subject of Research: Non-redundant negative regulation of TH17-mediated inflammation by the nuclear receptor REV-ERBβ

Article Title: Negative regulation of T H 17-mediated inflammation by the nuclear receptor REV-ERBβ

Article References: Campbell, S., Mosure, S. A., Amir, M., Chuck, J., Lu, Q., & Solt, L. A. (2026). Negative regulation of TH17-mediated inflammation by the nuclear receptor REV-ERBβ. iScience, 29(11), Article 117577. https://doi.org/10.1016/j.isci.2026.117577

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117577

Keywords: REV-ERBβ, REV-ERBα, TH17 cells, autoimmunity, nuclear receptor, IL-17A, EAE, colitis, NCoR1, heme, circadian clock, inflammation

The research team, led by Andriy Anishkin, Sangita Kachhap, and Sree V. Chintapalli across institutions including the University of Maryland and the Arkansas Children’s Nutrition Center, focused on two closely related metabolic cargo molecules. The first is palmitate, a sixteen-carbon saturated fatty acid that circulates abundantly in the bloodstream. The second is palmitoylcarnitine, the same fatty acyl chain but shuttled on a carnitine headgroup, the form in which long-chain fatty acids cross into mitochondria for beta-oxidation. Earlier work from the same group had shown that oxygenated myoglobin binds both molecules in a hydrophobic pocket near the heme, and that acylcarnitines actually grip the protein more tightly than free fatty acids do. What remained unknown was whether this bound cargo changes the protein’s behavior once it reaches the mitochondrial surface.

To answer that question, the team turned to molecular dynamics simulations, a technique that models every atom of a protein and membrane as they jiggle, rotate, and interact according to the laws of physics. They built two physiologically distinct models of the outer mitochondrial membrane. The first, an average-composition membrane, reflected the typical mixture of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and other headgroups found across the mitochondrial surface. The second, a contact-site membrane, was enriched in cardiolipin, a doubly charged phospholipid that clusters at specialized regions where the outer and inner mitochondrial membranes come into close apposition. Cardiolipin is best known as a signature lipid of the inner membrane, but its presence at contact sites makes those patches distinctly more negatively charged than the rest of the surface.

Into each membrane environment the researchers placed oxygenated myoglobin carrying either palmitate or palmitoylcarnitine, testing six different starting orientations of the protein so that no single docking pose would dominate the results. The simulation protocol unfolded in three stages. First, a weak steering force of roughly eleven piconewtons nudged each protein toward the membrane over forty nanoseconds, allowing thermal motion to rotate and reposition the complex so the final contact configuration depended little on the initial orientation. Then the external force was removed entirely, and each system relaxed for another forty nanoseconds to see whether the newly formed contacts would hold. Finally, a steered molecular dynamics phase pulled the protein away from the membrane at a constant velocity, recording the force required to break the association.

The results were striking in two ways. First, both lipid-bound forms of oxygenated myoglobin showed a clear preference for the cardiolipin-rich contact-site membrane over the average-composition membrane. The stability of the association, measured by how many protein-membrane atomic contacts survived the unrestrained relaxation phase, was 2.3-fold higher at the contact site for palmitate-bound myoglobin and 2.7-fold higher for palmitoylcarnitine-bound myoglobin. This mirrors the team’s earlier finding that unliganded oxygenated myoglobin also favors contact-site regions, and it suggests that cardiolipin’s negative charge acts as a general electrostatic beacon for the oxygen-carrying protein.

But the second result is what makes the new study stand out: the identity of the bound lipid changed everything about how the protein behaved at the membrane. Palmitate-bound myoglobin was ten to twenty percent more stable overall than its palmitoylcarnitine-bound counterpart, and when the researchers pulled the complexes off the membrane, palmitate-bound myoglobin required roughly twice the detachment force. At the contact-site membrane, the average detachment forces were 74.7 piconewtons for the palmitate complex versus 40.8 piconewtons for the palmitoylcarnitine complex. Lipid-specific contact analysis revealed why the two complexes behaved so differently: palmitate-bound myoglobin was strongly stabilized by cardiolipin, while palmitoylcarnitine-bound myoglobin leaned instead on phosphatidylethanolamine and phosphatidylinositol, with a smaller contribution from cardiolipin.

What makes this divergence remarkable is that the two cargo molecules share the identical sixteen-carbon palmitoyl chain. The only meaningful difference is the polar headgroup: palmitate carries a carboxylate, while palmitoylcarnitine carries the bulkier carnitine moiety. Yet that single chemical distinction was enough to rewire the entire network of protein-lipid contacts. Residue-level mapping showed that lysine-rich regions of the protein, particularly around helix F and the loop connecting helices C and D, dominated the membrane interactions, but the relative contributions of individual residues shifted depending on which lipid was bound. The authors emphasize that membrane stabilization was distributed across multiple residues and lipid species rather than concentrated at a single interaction site, pointing to a multicomponent, orientation-dependent mode of association.

The orientation result may prove to be the most consequential. In several palmitoylcarnitine-bound configurations, the heme crevice, the structural gateway through which oxygen enters and exits myoglobin, faced toward the membrane, whereas the more firmly anchored palmitate complex tended to adopt different membrane-facing poses. The researchers are careful to note that they did not directly simulate or measure oxygen release, so these orientation differences cannot yet be interpreted as evidence of faster or slower oxygen delivery. Still, the structural implications are tantalizing, because recent experimental work has shown that membrane contact itself perturbs the heme environment. A 2026 study in the Journal of the American Chemical Society reported that association with model liposomes roughly doubled the rate of oxygen dissociation from myoglobin, and complementary resonance Raman experiments showed that membrane-mimicking surfaces weaken the iron-oxygen bond. If the membrane is not just a docking site but an active participant in unloading oxygen, then the orientation of the heme crevice relative to the membrane surface becomes a potentially critical variable, and one that the bound metabolite appears to control.

The physiological context gives the finding real weight. Long-chain acylcarnitines accumulate in the blood and tissue when mitochondrial fatty acid oxidation falls behind substrate supply, a situation that arises during myocardial ischemia and in various metabolic disorders. Endurance exercise, fasting, and dietary fat intake all shift the balance between free fatty acids and acylcarnitine intermediates in muscle. The new simulations suggest that these metabolic fluctuations could change not just how much lipid-bound myoglobin sits at the mitochondrial surface, but in what configuration, potentially coupling oxygen delivery to the cell’s current fuel mix. The authors also point toward broader nutrient-sensing pathways such as mTORC1, which governs lipid metabolism and mitochondrial function, as a possible upstream regulator of the fatty acid and acylcarnitine pools that myoglobin encounters.

The study has clear limitations that the authors acknowledge candidly. Their membrane models contained only phospholipids, omitting the integral and peripheral proteins that crowd the real outer mitochondrial membrane, and the detachment forces measured under nonequilibrium pulling conditions cannot be read as equilibrium binding affinities. Oxygen release and lipid transfer were not directly measured, and the sampling, though broadened by six starting orientations per condition, represents a subset of the full conformational landscape. Even so, the central message is hard to escape: myoglobin’s metabolic cargo is not a passenger but a steering wheel. The same protein, carrying the same acyl chain, grips the mitochondrial surface with different strength, different lipid preferences, and different geometry depending on whether that chain arrives as a free fatty acid or a carnitine ester. Future experiments that directly measure oxygen release kinetics and lipid transfer from these complexes will determine whether this structural plasticity translates into a genuine regulatory mechanism, one that could tie the rhythm of cellular respiration to the shifting tides of fat metabolism in working muscle.

Subject of Research: How fatty acid and acylcarnitine binding modulates oxygenated myoglobin's interaction with the outer mitochondrial membrane

Article Title: Long-chain fatty acid- and acylcarnitine-bound oxygenated myoglobin interactions with outer mitochondrial membrane

Article References: Anishkin, A., Kachhap, S., Adepu, K. K., Sturms, R., Ulaganathan, V., & Chintapalli, S. V. (2026). Long-chain fatty acid- and acylcarnitine-bound oxygenated myoglobin interactions with outer mitochondrial membrane. Frontiers in Bioinformatics, 6, Article 1986755. https://doi.org/10.3389/fbinf.2026.1986755

Image Credits: AI Generated

DOI: 10.3389/fbinf.2026.1986755

Keywords: myoglobin, mitochondria, molecular dynamics, palmitate, palmitoylcarnitine, cardiolipin, outer mitochondrial membrane, oxygen transport, fatty acid metabolism, acylcarnitines, heme, simulations

The original study, published in August 2026, was an exploratory translational proteomics investigation. Rather than examining blood, the researchers turned to cerebrospinal fluid, the clear liquid that bathes the brain and spinal cord and that often reflects biochemical events happening inside the skull far more faithfully than peripheral blood does. Using proteomic analysis, they identified hemopexin as a molecule of interest, reporting that its levels in cerebrospinal fluid appeared to track with the later development of secondary sepsis and with in-hospital outcomes in patients who had suffered a spontaneous intracerebral hemorrhage, a devastating form of stroke caused by a ruptured blood vessel inside the brain.

Hemopexin is not an arbitrary candidate. It is the body’s highest-affinity binder of free heme, the iron-containing molecule at the heart of hemoglobin. When blood cells rupture, as they do in large quantities after an intracerebral hemorrhage, heme is released into surrounding tissues and fluids. Free heme is a double-edged molecule: it is essential for life, but in its unbound form it catalyzes the formation of reactive oxygen species, damages cell membranes, and amplifies inflammation. Hemopexin acts as a molecular sponge, sequestering heme and escorting it to receptors that clear it from the extracellular space. In the brain, where hemorrhage floods tissue with hemoglobin breakdown products, hemopexin sits at the front line of the body’s attempt to contain the damage.

That biology is precisely why the protein has attracted attention before. A 2018 study published in the Journal of Cerebral Blood Flow and Metabolism by Leclerc and colleagues reported that increased brain hemopexin levels improved outcomes after intracerebral hemorrhage in experimental models, supporting the idea that the protein is protective rather than merely a passive marker of bleeding. Against that backdrop, the new proteomic finding that cerebrospinal fluid hemopexin might signal something as seemingly distant as sepsis, a systemic infection-driven syndrome, was provocative. It suggested that the biochemical storm unleashed by brain injury and the immune collapse of sepsis might be connected through measurable molecular threads.

The letter to the editor, authored by Ahmed H and Niazi M and entitled Cerebrospinal Fluid Hemopexin as a Sepsis-Specific Signal After Intracerebral Hemorrhage, challenged that interpretation. Letters of this kind are a standard mechanism of scientific self-correction: they allow outside experts to interrogate a study’s assumptions, methods, and conclusions in public. The correspondents appear to have questioned whether the hemopexin signal truly represents a sepsis-specific phenomenon, or whether it might instead reflect more general processes, such as the sheer volume of bleeding, blood-brain barrier disruption, or the intensity of the inflammatory response to the hemorrhage itself. That distinction matters enormously, because a biomarker that merely tracks injury severity would be far less useful for clinical decision-making than one that specifically predicts a treatable complication like infection.

In their formal response, published on October 6, 2026, Xie and colleagues defended their work while engaging with the critique. The response, prepared by the same team from the Department of Critical Care Medicine at Huashan Hospital, addressed the methodological concerns raised by the correspondents. Among the references cited in the exchange is a landmark methodological paper by Riley and colleagues in the British Medical Journal on calculating the sample size required for developing a clinical prediction model, a detail that signals the debate touched on the statistical foundations of biomarker research. Prediction models, unlike simple association studies, are intended to generate risk estimates for individual patients, and the field has learned through painful experience that models built on small samples with too many variables tend to fail when tested on new patients.

That concern is especially acute in sepsis research after intracerebral hemorrhage. Patients with brain bleeds are among the most vulnerable in the intensive care unit: they may be immobile, intubated, unable to protect their airways, and fitted with invasive devices, all of which raise infection risk. Detecting sepsis early in such patients is notoriously difficult because the classic signs, fever, elevated heart rate, abnormal white blood cell counts, can be produced by the brain injury itself. A 2025 multicenter retrospective study published in the Journal of Medical Internet Research by Liu and colleagues attempted to build an explainable prediction model for sepsis in patients with intracerebral hemorrhage, underscoring both the clinical demand for such tools and the methodological rigor required to build them credibly. Against this landscape, any proposed biomarker, particularly one drawn from an invasive fluid like cerebrospinal fluid, must clear a high evidentiary bar.

The Shanghai team’s response also reflects the realities of exploratory translational science. The original study was explicitly framed as exploratory, a word that carries weight in the biomarker literature. Exploratory proteomics studies generate hypotheses; they do not, on their own, establish clinical validity. The researchers acknowledged the preliminary nature of their findings while maintaining that hemopexin deserves continued investigation as a candidate marker. Their response, like the original study, was published without dedicated funding, and the authors declared no conflicts of interest. They also disclosed that ChatGPT was used solely for English language editing, with all authors reviewing and verifying the final content, a level of transparency about artificial intelligence use that has become increasingly expected in biomedical publishing.

What makes this exchange worth watching is what it reveals about the path from a proteomic discovery to a bedside test. For cerebrospinal fluid hemopexin to become a genuine clinical tool, several hurdles remain. The finding would need independent replication in larger, ideally multicenter cohorts. Researchers would need to demonstrate that hemopexin adds predictive value beyond existing clinical variables such as hemorrhage volume, location, Glasgow Coma Scale score, and standard inflammatory markers. They would need to establish whether serial measurements, rather than a single time point, improve prediction. And because lumbar puncture is invasive and not without risk in patients with mass lesions in the brain, the practical case for a cerebrospinal fluid marker would need to be compelling, or the signal would need to be mirrored in blood.

The deeper scientific question raised by the letter, whether hemopexin is a sepsis-specific signal or a general readout of injury and inflammation, is exactly the kind of question that rigorous debate is designed to resolve. If hemopexin turns out to be a broad marker of heme burden and barrier disruption, it may still be valuable, perhaps as an indicator of secondary brain injury. If it is genuinely specific to the transition toward systemic infection, it could open a window into the poorly understood mechanisms by which catastrophic brain injury destabilizes systemic immunity. Either answer would advance the field; the current exchange ensures the question is asked properly. For now, the verdict of the scientific process is still pending, and patients with intracerebral hemorrhage, who face sepsis as one of the most dangerous complications of their condition, await the larger studies that will determine whether this heme-scavenging protein can deliver on its early promise.

Subject of Research: Cerebrospinal fluid hemopexin as a candidate biomarker for secondary sepsis after spontaneous intracerebral hemorrhage

Article Title: Response to the Letter to the Editor Entitled “Cerebrospinal Fluid Hemopexin as a Sepsis-Specific Signal After Intracerebral Hemorrhage” Regarding the Study “Cerebrospinal Fluid Hemopexin as a Candidate Biomarker for Secondary Sepsis and In-hospital Outcome After Spontaneous Intracerebral Hemorrhage: An Exploratory Translational Proteomics Study”

Article References: Xie, T., Feng, W., He, Y., Cao, Y., & Deng, S. (2026). Response to the Letter to the Editor Entitled “Cerebrospinal Fluid Hemopexin as a Sepsis-Specific Signal After Intracerebral Hemorrhage” Regarding the Study “Cerebrospinal Fluid Hemopexin as a Candidate Biomarker for Secondary Sepsis and In-hospital Outcome After Spontaneous Intracerebral Hemorrhage: An Exploratory Translational Proteomics Study”. Neurocritical Care. https://doi.org/10.1007/s12028-026-02663-4

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02663-4

Keywords: hemopexin, cerebrospinal fluid, sepsis, intracerebral hemorrhage, biomarkers, proteomics, neurocritical care, heme, prediction models, inflammation, stroke, critical care